These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9703328)

  • 1. Cloning of the promoters for the beta-cell ATP-sensitive K-channel subunits Kir6.2 and SUR1.
    Ashfield R; Ashcroft SJ
    Diabetes; 1998 Aug; 47(8):1274-80. PubMed ID: 9703328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated expression of adenosine triphosphate-sensitive potassium channel subunits in pancreatic beta-cells.
    Moritz W; Leech CA; Ferrer J; Habener JF
    Endocrinology; 2001 Jan; 142(1):129-38. PubMed ID: 11145575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the mouse sulfonylurea receptor 1 promoter and its regulation.
    Hernández-Sánchez C; Ito Y; Ferrer J; Reitman M; LeRoith D
    J Biol Chem; 1999 Jun; 274(26):18261-70. PubMed ID: 10373428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
    Gribble FM; Tucker SJ; Seino S; Ashcroft FM
    Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).
    Gloyn AL; Hashim Y; Ashcroft SJ; Ashfield R; Wiltshire S; Turner RC;
    Diabet Med; 2001 Mar; 18(3):206-12. PubMed ID: 11318841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel.
    Gros L; Virsolvy A; Salazar G; Bataille D; Blache P
    Biochem Biophys Res Commun; 1999 Apr; 257(3):766-70. PubMed ID: 10208857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
    Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
    Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a novel member of the ATP-sensitive K+ channel subunit family, Kir6.3, in zebrafish.
    Zhang C; Miki T; Shibasaki T; Yokokura M; Saraya A; Seino S
    Physiol Genomics; 2006 Feb; 24(3):290-7. PubMed ID: 16317080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
    Cui Y; Tinker A; Clapp LH
    Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKA-mediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation.
    Béguin P; Nagashima K; Nishimura M; Gonoi T; Seino S
    EMBO J; 1999 Sep; 18(17):4722-32. PubMed ID: 10469651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
    Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
    Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy.
    Cartier EA; Conti LR; Vandenberg CA; Shyng SL
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2882-7. PubMed ID: 11226335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.
    Florez JC; Burtt N; de Bakker PI; Almgren P; Tuomi T; Holmkvist J; Gaudet D; Hudson TJ; Schaffner SF; Daly MJ; Hirschhorn JN; Groop L; Altshuler D
    Diabetes; 2004 May; 53(5):1360-8. PubMed ID: 15111507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.
    Kawaki J; Nagashima K; Tanaka J; Miki T; Miyazaki M; Gonoi T; Mitsuhashi N; Nakajima N; Iwanaga T; Yano H; Seino S
    Diabetes; 1999 Oct; 48(10):2001-6. PubMed ID: 10512365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion.
    Huopio H; Vauhkonen I; Komulainen J; Niskanen L; Otonkoski T; Laakso M
    Diabetes Care; 2002 Jan; 25(1):101-6. PubMed ID: 11772909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle.
    Sakura H; Ammälä C; Smith PA; Gribble FM; Ashcroft FM
    FEBS Lett; 1995 Dec; 377(3):338-44. PubMed ID: 8549751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic overexpression of SUR1 in the heart suppresses sarcolemmal K(ATP).
    Flagg TP; Remedi MS; Masia R; Gomes J; McLerie M; Lopatin AN; Nichols CG
    J Mol Cell Cardiol; 2005 Oct; 39(4):647-56. PubMed ID: 16099470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2.
    Mukai E; Ishida H; Horie M; Noma A; Seino Y; Takano M
    Biochem Biophys Res Commun; 1998 Oct; 251(2):477-81. PubMed ID: 9792799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of sarcolemmal ATP-sensitive potassium channel activity impairs the cardiac response to systolic overload.
    Hu X; Xu X; Huang Y; Fassett J; Flagg TP; Zhang Y; Nichols CG; Bache RJ; Chen Y
    Circ Res; 2008 Oct; 103(9):1009-17. PubMed ID: 18802029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone.
    McKay NG; Kinsella JM; Campbell CM; Ashford ML
    Br J Pharmacol; 2000 Jun; 130(4):857-66. PubMed ID: 10864893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.